At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension
In Brief
A Phase 4 clinical trial evaluating 0.1% brimonidine tartrate ophthalmic solution, 0.01% bimatoprost ophthalmic solution, and 2 other interventions for Glaucoma and Ocular Hypertension. Completed, enrolled 137 participants across 1 site.
Detailed Summary
This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P) in combination in patients previously treated with latanoprost 0.005% ophthalmic solution monotherapy who require additional intraocular pressure (IOP) lowering medication.
Study Details
Timeline
Interventions
1 drop of 0.1% brimonidine tartrate ophthalmic solution 3 times per day for 12 weeks.
1 drop of 0.01% bimatoprost ophthalmic solution once per day for 12 weeks.
1 drop of 0.2% hypromellose lubricant eye drops 3 times per day for 12 weeks.
1 drop of latanoprost 0.005% ophthalmic solution once daily as run-in therapy for 30 days only.